|
Effective immediately, NRG-BN010, “A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma,” dose level 2 is temporarily closed to accrual for a protocol-specified analysis of safety and tolerability.
The trial will be temporarily closed for at least 2 months. A broadcast regarding reopening will be sent when the protocol-specified toxicity analysis is complete.
Reminder: Data collection and site IRB renewal for closed studies must continue until the study is terminated.
Please distribute this information to the appropriate personnel at participating affiliate institutions.
| 
